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ABSTRACT 
 
 
Continuous infusion with native gonadotropin-releasing hormone (GnRH) 
restores follicular growth and ovulation in approximately 85% of winter anovulatory 
mares. However, the potential role of estradiol-17β (E2) in enhancing pituitary 
responsiveness to GnRH during this transitional process is unclear. Moreover, the 
contribution of follicle-stimulating hormone (FSH) to the overall response has not been 
studied. Objectives herein were to test the hypotheses that (1) continuous treatment with 
either a low or high dose of E2 enhances pituitary responsiveness to continuous infusion 
of native GnRH, and (2) the pattern of FSH secretion mimics that of LH. Twenty-four 
winter anovulatory mares were stratified by body weight and body condition score, and 
assigned randomly to 1 of 4 treatments (n = 6/treatment) in early February: 1) Control; 
Silastic® subcutaneous (S.C.) sham pump, 2) GnRH; native GnRH in saline via 14-day 
Alzet® osmotic pump (100 µg/h, S.C.), 3) GnRH + High E2; GnRH as in 2 plus 
Compudose® E2 implant, (25.7-mg, S.C.), and 4) GnRH + Low E2; GnRH as in 2 and 3 
plus 1/4-length E2 implant (6.425-mg, S.C.). Plasma concentrations of LH, FSH, E2, 
estrone sulfate, and progesterone were measured in daily blood samples. Mares 
developing 35-mm follicles were induced to ovulate with human chorionic gonadotropin 
(hCG). Mares not ovulating within 14 days received a second 14-day GnRH pump. 
Although acute increases in uterine edema observed within 48 hours indicated implant 
functionality,  plasma E2 and estrone sulfate were increased primarily in association 
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with a large, dominant follicle. Plasma LH was increased in all GnRH-treated mares, 
regardless of ovarian response, but was unaffected by E2. By Day 28, 6/6 GnRH, 5/6 
GnRH + Low E2, 2/6 GnRH + High E2, and 0/6 Control mares developed a 35-mm 
follicle and were induced to ovulate. A peak of FSH was observed in response to all 
GnRH treatments at 24 hours, with plasma FSH returning to baseline by day 4. 
Therefore, the hypotheses were not supported as the subcutaneous E2 implants failed to 
enhance responsiveness of mares to GnRH and the release of FSH in response to GnRH 
infusion did not mimic the LH release pattern. 
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NOMENCLATURE 
 
GnRH Gonadotropin-releasing hormone 
E2 Estradiol-17β 
EB Estradiol benzoate 
LH Luteinizing hormone 
FSH Follicle-stimulating hormone 
P4 Progesterone 
CL Corpus luteum 
CH Corpus hemorragicum  
OVX Ovariectomized  
BW Body weight 
BCS Body condition score 
RIA Radioimmunoassay 
IGF-1 Insulin-like growth factor-1 
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I. INTRODUCTION
The horse is a seasonally reproductive livestock species in which estrous 
cyclicity coincides with long-day photoperiod and is observed during the late spring, 
summer and early fall months. Transition from the anovulatory to ovulatory state begins, 
in general, around the time of the vernal equinox (March 22 and September 22 in the 
northern and southern hemispheres, respectively). On average, mares in North America 
exhibit their first ovulation in early April (April 7 ± 9.1 days) [1,2]. By the summer 
solstice (June 20-21), 95-100 % of mares exhibit regular 19- to 24-day estrous cycles 
until approximately the time of the autumnal equinox (September 22), at which time the 
proportion of mares ovulating and peripheral luteinizing hormone (LH) concentrations 
decline slowly. Individual mares in certain years will continue to ovulate well into the 
fall and early winter, with 15-30% of mares in a given year continuing to cycle 
throughout the winter period [3,4]. 
Many horses are valued for their performance and recreational purposes, placing 
emphasis on the pedigree of the animal. Pedigree value is increased by accredited 
registration of the horse and its progeny. In the northern hemisphere, the majority of 
breed registries employ a universal birthdate of January 1. Thus, horses are officially 
considered a year older on each subsequent January 1, regardless of actual birth date. 
The universal birthdate promotes an incentive for owners and breeders to create an 
operational breeding season that is in advance of the natural season, and its transitional 
period, by approximately 2 months [4]. Foals born earlier in the year have an advantage 
1  
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in size and maturity compared to those born later in the year. A variety of managerial 
and pharmacological treatments have previously been investigated for their capability to 
artificially hasten the onset of cyclicity and ovulation in winter anovulatory mares, and 
have been evaluated for their practicality in a normal management setting as described 
below. 
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II. REVIEW OF LITERATURE 
2.1. Gonadotropin profile of the mare  
During the luteal phase and early follicular phases of the estrous cycle, follicle-
stimulating hormone (FSH) is secreted to stimulate a cohort of follicles to grow. 
Follicles are selected and one, sometimes two, follicles undergo deviation, whereby the 
follicle(s) grow in diameter and develop endocrine capacities necessary for ovulation 
[2,4]. As follicle selection and deviation take place, the dominant follicle (or follicles 
where 2 large follicles are selected) gains the capacity to synthesize and secrete inhibin 
from granulosa cells. This ovarian glycoprotein acts at the pituitary to inhibit secretion 
of FSH and accounts for the decline of circulating FSH as the dominant follicle matures. 
Other intra-follicular factors, including insulin-like growth factor 1 (IGF-1) and 
follistatin, also contribute to negative feedback regulation of FSH [5]. The dominant 
follicle gradually synthesizes and secretes increasing quantities of estradiol-17β (E2), 
peaking approximately 4 to 6 days before ovulation [6]. Unaffected by inhibin and under 
positive influence from GnRH, LH pulses become more frequent after luteal regression 
and, together with increasing amplitude, increases circulating concentrations of LH to 
values that result in ovulation of the preovulatory follicle [7]. After ovulation occurs, LH 
triggers the luteinization of the follicle, initially forming a corpus hemorrhagicum and 
then a corpus luteum (CL). The CL functions to synthesize and secrete progesterone 
(P4), resulting in circulating concentrations indicative of a functional CL (> 1.0 ng/mL) 
[8]. At CL regression, progesterone concentrations decline to a baseline well below 1.0 
ng/mL where it remains until formation of the next CL [8]. 
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2.2. Neuroendocrine seasonality 
During the winter months, or short days, the nightly duration of melatonin 
secretion from the pineal gland is increased relative to that occurring during long-day 
photoperiod. In the mare, the pineal gland entrains the photoperiodic circadian rhythm as 
demonstrated by the lack of response to photoperiod after pinealectomy or superior 
cervical ganglionectomy [9,10]. The seasonal disruption in reproductive cyclicity also 
depends on a photorefractory response, photoperiodic response history, and an 
established photosensitive period [11]. During periods of decreased photoperiod, LH β-
subunit synthesis is down-regulated and LH secretion is suppressed [12]. Interestingly, 
FSH in equids does not exhibit a seasonal decline in the peripheral circulation [12]. Due 
to the suppression of LH synthesis and secretion, approximately 85% of light horse 
mares enter a period of anovulation in the winter, and ovarian follicles do not grow to 
ovulatory size [4]. During the spring transitional period, as defined by the period of 
lengthening photoperiod, the proportion of mares ovulating directly corresponds to the 
increase in peripheral concentrations of LH, and ovarian activity resumes as a result of 
the effects of LH on follicle maturation and ovulation [13]. At this time, the pattern of 
ovarian follicular growth undergoes a drastic change as follicular waves emerge in 
which a large follicle is selected, deviates from the rest of the follicles in the wave, and 
develops into a dominant follicle capable of undergoing ovulation. During the process of 
selection and deviation, the two larger follicles generally develop in tandem, increasing 
in diameter until one follicle is selected and undergoes deviation at approximately 22 
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mm. The subordinate follicle regresses and becomes atretic, while the selected follicle 
continues to mature and reaches periovulatory status at approximately 30 mm [4]. 
2.3. Artificial photoperiod 
 Photoperiod has been well documented as the primary factor regulating seasonal 
reproduction in the horse [2,4,9,10,14,15]. Manipulation of light exposure has varying 
effects on hastening the onset of ovulation in the winter anovulatory mare. In an early 
study, artificially exposing mares to a total of 16 hours of light and 8 hours of dark in a 
24-hour period was shown to be effective in accelerating the onset of first ovulation in 
the mare when begun December 1, although the exact ratio of light to dark could vary 1 
to 2 hours [14]. A protocol termed flash lighting has also been effective in stimulating 
the advancement of seasonality and requires less electricity and light exposure. 
Beginning around 4:00 am, or approximately 9 hours after dusk, the protocol requires 
mares to be subjected to a 1-hour pulse of light, in addition to the natural exposure to 
daylight [14].  
 More recently, a technology called Equilume has been developed (Equilume Ltd, 
Co. Kildare, Ireland). A mask, similar to those used in racing, is equipped with a quarter-
cup over the right eye. The cup houses a blue LED light that is programmed to activate 
long enough to expose the eye to the full 16:8 hour light to dark ratio and has been 
shown to stimulate early transition and cyclicity comparable to the traditional artificial 
lighting protocol [16]. Though this technology eliminates the necessity of costly 
infrastructure for broodmares, the masks are currently battery operated and require a 
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significant investment of at least $400 USD per unit, which may limit industry-wide 
application.  
 Regardless of the lighting protocol, artificial lighting regimens have been shown 
to produce variable responses in studies involving large numbers of mares and require 
significant investments in labor, time, and infrastructure to implement [17]. Thus, other 
options such as use of pharmacological agents have been pursued.  
 
2.4. Pharmacological therapies to advance seasonality 
2.4.1. Melatonin 
 As described previously, melatonin is believed to be the primary photoperiodic-
driven hormonal cue that modulates GnRH and gonadotropin secretion in response to 
photoperiod. In ewes, melatonin microimplants inserted into the pre-mammillary 
hypothalamic area were able to stimulate the secretion of LH, and have the ability to 
hasten onset of seasonal estrous activity [18]. However, when ovariectomized (OVX) 
pony mares were treated with subcutaneous melatonin implants during the breeding 
season, no effects on circulating concentrations of LH, E2, or P4 were observed [19]. In 
intact mares, secretion of GnRH and LH was increased and the last ovulation of the 
breeding season was delayed following treatment with subcutaneous melatonin implants 
[19]. However, in the same study, long-term treatment with melatonin delayed 
significantly the onset of the subsequent breeding season, suggesting that exogenous 
melatonin treatment can alter the circannual rhythm [20]. Other studies involving 
treatment with melatonin have resulted in variable effects on secretion of LH and 
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evidence for a potential interaction with prolactin, suggesting that melatonin treatment 
alone does not accelerate consistently the timing of reproductive transition and first 
ovulation in the winter anovulatory mare [21,22]. 
2.4.2. Opioids 
The secretion of GnRH, and thus gonadotropins, is reduced in the presence of 
heightened opioid tone within the hypothalamus [23,24].  Evidence suggests that 
endogenous opioid peptides may play a role in regulating equine seasonal reproduction. 
After administration of the opioid antagonist, naloxone, circulating concentrations of LH 
increased significantly in winter anovulatory mares [25-27] and this response may be 
related to dose [26] and season [28,29]. A bolus, intravenous (iv) injection of naloxone 
during the breeding season had a similar effect, but increased secretion of GnRH and 
FSH was also documented [30]. Davidson et al. suggested that due to the inhibitory 
nature of endogenous opioids on gonadotropin secretion, reduced opioid tone could 
explain the minority of mares that continue to cycle throughout the year [29]. Although 
data suggests endogenous opioids play a role in modulating GnRH and gonadotropins, 
this role and how it relates to reproductive seasonality in the mare remains to be 
completely defined.  
2.4.3. Catecholamines 
After it was discovered in 1990 that concentrations of catecholamines, including 
dopamine, were greater in cerebrospinal fluid during the anovulatory season in mares 
compared to the breeding season [31], dopamine antagonists were tested for their ability 
to advance vernal reproductive transition. While some studies have shown that dopamine 
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antagonists can stimulate follicular development and decrease the time to first ovulation 
[32-34], others including those involving long-term application, have reported limited to 
no effect on gonadotropin secretion or ovulation [33-37]. A recent study, however, 
reported that pre-treatment with estradiol benzoate (EB) prior to injection of sulpiride, a 
dopamine antagonist, hastened the onset of first ovulation and increased both LH and 
prolactin concentrations in seasonally anovulatory mares compared to mares given 
sulpiride alone [38]. In that same study, it was hypothesized that the pre-treatment of EB 
increased the response of winter anovulatory mares to the dopamine antagonist [38]. 
Despite inconclusive evidence for the ability of dopamine antagonists to advance 
the onset of ovulation, concentrations of prolactin, whose secretion is negatively 
controlled primarily by dopamine, increase with the lengthening photoperiod and 
heightened temperatures associated with onset of the breeding season [33,37,39]. 
Prolactin receptor immunohistochemical cell staining has been reported to be most 
intense in large antral follicles, providing further evidence of a possible mechanistic role 
of prolactin during follicular maturation and potentially ovulation [40]. It has been 
suggested that prolactin is needed for LH receptor numbers to be adequate for ovulation 
in the female rat [41], though this potential role of prolactin has not been described in the 
mare. 
Exogenous prolactin treatment in winter anestrous mares induced early vernal 
hair shedding, estrus, and ovulation; however, with little effect on concentrations of LH 
compared to untreated, control mares [42], supporting the possibility that prolactin 
works via receptor population. A role of prolactin in seasonal reproductive cyclicity is 
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supported by observations that lactotroph populations in the pars distalis are more 
numerous during the breeding season compared to the non-breeding season in the mare 
[43]. There is also evidence that gonadotrophs in the pars distalis colocalize with 
lactotrophs, indicating the possibility of cross-talk between the two cell populations 
[43,44]. In the ewe, increased lactotroph cytoplasmic area, greater rough endoplasmic 
reticulum populations, and increased density of prolactin-secreting granules are also 
reported during the breeding season when compared to the non-breeding season [45]. 
Thus, it has been proposed that increased circulating concentrations of prolactin, 
accompanied by parallel increases in dopaminergic cell populations, may account for the 
mare’s ability to reduce pituitary desensitization of the GnRH receptor during the 
breeding season [46].  
The ability of GnRH to stimulate prolactin secretion has been investigated in 
ovine pituitary cell cultures. In those experiments, GnRH stimulated a dose-dependent 
increase in prolactin release during the breeding season in the ewe, a short-day 
reproductive species [47]. This effect was completely inhibited by a dopamine agonist 
[47]. The relative impact of these interrelationships in the mare, however, has yet to be 
investigated.  
2.4.4. GnRH 
 It has been well established that an endogenous, intermittent hypophysiotropic 
signal of GnRH is required to optimally stimulate the synthesis and secretion of LH 
necessary for ovulation [48,49]. Native GnRH and several synthetic GnRH agonists 
(buserelin, deslorelin, histerelin, goserelin) have been used both experimentally and 
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clinically to induce ovulation in cattle (native GnRH) and horses (GnRH agonists). In 
winter anovulatory and transitional mares, it was hypothesized that these analogues 
could stimulate the hypothalamic-pituitary-ovarian axis sufficiently to elevate peripheral 
concentrations of LH to induce follicular development and ovulation. Although buserelin 
injections have been effective in accelerating the time of ovulation and pregnancy in the 
winter anovulatory mare compared to untreated mares [50], later studies revealed the 
agonists’ tendency to temporarily desensitize pituitary gonadotropes when given in 
either repeated injections or implant [51-53]. This most likely occurs due to the much 
greater affinity of the agonists for the gonadotrope receptor resulting in delayed 
clearance and related receptor down-regulation [51-53]. Temporary pituitary 
desensitization was further supported when a single implant of deslorelin was efficient in 
stimulating ovulation, but prevented LH and FSH response to a GnRH challenge, with 
suppression lasting until 10 days post-ovulation [54]. Despite the apparent ability of 
GnRH agonists to stimulate ovulation in winter anovulatory mares, the pituitary 
desensitization and subsequent suppression of gonadotropins makes synthetic agonists 
undesirable for consistently hastening the onset of regular estrous cyclicity in the mare. 
 Native GnRH does display the same capacity to down-regulate receptors 
compared to GnRH agonists in the winter anovulatory mare. Early studies showed that 
hourly, intravenous injections of native GnRH in doses ranging from 2 to 20 µg/hour 
were able to significantly increase peripheral concentrations of LH and accelerate 
ovulation in seasonally anestrous mares [55,56]. Though this method of delivery best 
mimics the endogenous hypophysiotropic signal [48,49,55,56], hourly pulsatile 
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injections are not practical. Therefore, numerous studies have investigated the efficacy 
of subcutaneous delivery of the native hormone. Although continuous subcutaneous 
infusion of native GnRH does not increase peripheral LH to breeding season values, it is 
capable of elevating concentrations of LH in both the winter anovulatory and cycling 
mares [57,58]. When administered at a rate of 100 µg/hour using an osmotic pump, 
native GnRH hastened the onset of first induced ovulation and pregnancy by 
approximately 2 months (response seen in 85% and 79% of winter anovulatory mares, 
respectively), compared to controls [59,60]. It is unclear, however, why 10-15% of 
winter anestrous mares failed to respond to the constant GnRH stimulus, requiring 
further investigation. 
 The method of delivery using the osmotic pump consists of surgically implanting 
it subcutaneously in the neck of the mare, cranial to the scapula [58-60]. Until a more 
user-friendly delivery method is devised that can be practically implemented in the 
equine breeding industry, its adoption will continue to be hindered.   
2.4.5. Estradiol 
Estradiol-17β is the primary biologically-active estrogen synthesized in 
mammalian systems and is produced in relatively large quantities by “estrogen-active”, 
dominant follicles in the mare that are approximately 20 mm or greater [6]. Circulating 
concentrations of E2 increase significantly about 6 to 8 days prior to ovulation, peaking 
approximately 2 days before ovulation [4]. The peak in E2 precedes the ovulatory peak 
of LH, suggesting a positive feedback of E2 on the hypothalamic-pituitary-ovarian axis 
during estrus [61], similar to that characterized in other mammalian females [62]. 
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Although the proposed manner of action remains to be defined in the mare, several 
studies have provided evidence that E2 stimulates increased pituitary content and 
peripheral concentrations of LH [63], but may create this effect by a method other than 
enhancing the pituitary response to GnRH [64].  Pre-treatment of mares with exogenous 
E2 prior to GnRH treatment enhanced circulating LH concentrations compared to those 
for controls [65]. However, in a more recent study, increasing doses of E2 led to 
decreased concentrations of LH in the estrual mare [66]. Studies in ovariectomized 
(OVX) mares have also resulted in inconclusive or ambiguous results. Miller et al. [67] 
reported that E2 decreased both LH and FSH initially, followed by a brief increase 12 
hours later. In another study involving OVX mares during the vernal transitional period, 
E2 had no effect on the secretion pattern of FSH, but had a positive effect on 
concentrations of LH [63]. When E2 was given twice daily in the OVX early transitional 
mare, there was a significant increase in both α and β LH subunit synthesis within the 
pituitary [68]. 
The effects of coincident treatment with E2 and GnRH have also been examined 
[65,69,70]. However, the interpretation of results is somewhat complicated because 
GnRH agonists were employed in several of the studies. As a result, it is difficult to fully 
ascertain the independent effects of E2 because of the possibility of GnRH receptor 
down-regulation in mares treated chronically with these agonists. A recent preliminary 
study performed in our laboratory tested the effects of continuous infusion of native 
GnRH simultaneously with daily injections of exogenous E2 [71]. Mean circulating 
concentrations of LH were increased slightly but significantly after 7 days in E2-treated 
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mares compared to GnRH only. Results were interpreted to indicate the possibility of 
enhanced sensitivity of gonadotropes to GnRH, in contrast to  previously findings [63].  
To the best of our knowledge, apart from the preliminary study described above, 
secretion of LH in response to physiologic versus pharmacologic doses of continuous 
exogenous E2 administered coincident with the continuous, subcutaneous infusion of 
native GnRH has not been investigated. In addition, the secretion patterns of FSH in 
response to chronic treatment with native GnRH, and the interactive effects of E2, have 
not been characterized in the winter anovulatory mare. A greater understanding of FSH 
secretory dynamics in response to continuous GnRH treatment may yield a better 
understanding of the physiology and endocrinology of the 10-15% of the winter 
anovulatory mare population that fails to respond to this treatment. Based on the 
foregoing knowledge, we designed a project to investigate the effectiveness of 
continuous, subcutaneous E2 in enhancing pituitary responsiveness of GnRH and to 
observe the resulting secretion pattern of FSH as it compares to LH in response to native 
GnRH or native GnRH + E2. 
  
________________________________ 
*Parts of this chapter have been reprinted from “Secretions of gonadotropins is
differentially regulated by continuous infusion of native GnRH and is unaffected by
exogenous estradiol in winter anovulatory mares” by O’Neil MM, Scarpa JO, Cardoso
RC, Williams GL. J Eq Vet Sci 2017; 52: 112. Copyright Elsevier 2017.
III. DIFFERENTIAL REGULATION OF GONADOTROPINS IN RESPONSE
TO CONTINUOUS INFUSION OF NATIVE GnRH IN THE WINTER
ANOVULATORY MARE: EFFECTS OF CONTINUOUS TREATMENT WITH 
LOW- OR HIGH-DOSE ESTRADIOL-17β IMPLANTS* 
3.1 Introduction 
Mares are long-day breeders, with resumption of pituitary-ovarian activity 
associated with increasing photoperiod following the spring equinox. Due to a widely- 
employed universal birthdate of January 1 in the northern hemisphere (July 1 in the 
southern hemisphere) by numerous breed registries, there is managerial incentive for 
professional breeders to accelerate the natural transition period by approximately 2 
months [4]. Foals born as close to, but after January 1, are more mature early in their 
second and third years of life. Thus, they have a competitive advantage over those born 
later in the season and are usually more valuable at auction [4,72]. Moreover, mares that 
foal earlier in the season have the opportunity to be bred back at an earlier date, thus 
enhancing the potential for production of another foal early in the subsequent season [2]. 
During the winter months, 85% of standard horse mares enter a period of winter 
anovulation [4] due to marked declines in pituitary synthesis and secretion of LH 
[12,73]. Overall mean circulating concentrations of FSH are unaffected by changing 
season [12,74,75]. However, increments in serum/plasma FSH are clearly required for 
the recruitment of each new follicle wave during established cycles, peaking at about the 
14 
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time of dominant follicle deviation [2,4].  During the winter months, anovulatory 
follicular waves can occur, but follicular diameters do not typically exceed 20 mm, and 
follicles become atretic [75]. It is not until the vernal transitional period that selected 
dominant follicles gain the capacity to secrete E2, reach preovulatory status, and exert 
positive feedback to induce the ovulatory surge of LH [75, 76]. 
The exogenous administration of GnRH agonists, such as buserelin and 
deslorelin, has been used successfully in mares to stimulate secretion of LH and induce 
ovulation of large follicles in winter anestrus [50]. However, when administered 
chronically as an injection or implant, GnRH agonists often lead to temporary pituitary 
desensitization of the gonadotropes, making them a less than optimal method of 
advancing reproductive transition despite variable success [50-53]. Notably, chronic 
administration of native GnRH in the mare is less likely to result in marked 
desensitization, particularly if administered during the non-breeding season when 
endogenous secretion of GnRH is low [55-60]. Hourly, intravenous injections of as little 
as 2 µg have been shown to markedly increase concentrations of LH and stimulate 
follicular development, maturation, and ovulation in winter anovulatory mares. 
However, hourly injections have limited practicality for professional breeders [55-56]. 
Although continuous infusion of native GnRH via an osmotic pump does not optimize 
pituitary responses or result in breeding season concentrations of peripheral LH, it is an 
effective alternative for increasing circulating concentrations of LH to values that rapidly 
stimulate development of a large follicle. This facilitates natural breeding or AI coupled 
with induced or natural ovulation up to 2 months earlier than typically expected [57-60]. 
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However, approximately 15% of mares consistently fail to respond to this treatment [57-
60]. Therefore, further studies are required to determine the basis of its failure. In this 
context, the pattern of FSH secretion and its role in modulating ovarian responsiveness 
to continuous infusion of native GnRH has not been studied. Moreover, there is 
conflicting evidence regarding the ability of E2 to increase secretion of LH during vernal 
transition or in response to continuous GnRH treatment [56,65]. In a preliminary study 
in our laboratory, twice daily intramuscular injections of EB, coincident with continuous 
infusion of native GnRH, led to modestly increased peripheral concentrations of LH 
compared to GnRH alone after 7 days [71].  
The objectives of the experiment reported here were to test the hypotheses that 1) 
continuous treatment with either a low (peripheral target ~ 20-25 pg/mL) or high 
(peripheral target of ~100 pg/mL) dose of E2 will enhance pituitary responsiveness to 
continuous infusion of native GnRH in winter anovulatory mares, and 2) the FSH 
response to GnRH or GnRH plus E2 treatments will mimic that of LH until deviation is 
reached by a newly-recruited large follicle. 
 
3.2 Materials and methods 
 All animal-related experiments were approved by the Institutional Agricultural 
Animal Care and Use Committee (IAACUC) of the Texas A&M University System 
(AUP #2016-002A). 
 
 
17 
3.2.1 Animals 
Twenty-four non-pregnant light horse mares, the majority being American 
Quarter Horses, were maintained on mixed grass pasture and supplemented with Coastal 
Bermuda or Alfalfa grass hay in order to maintain a body condition score (BCS) of a 5 to 
6 (on a 1 to 9 scale) [77] at the Texas A&M Agrilife Research Station in Beeville, Texas. 
3.2.2 Preliminary experiment 
In December, prior to the start of the formal study, a preliminary experiment was 
performed to confirm estrogenic effects of both a full and 1/4 E2 implant (Compudose® 
implants; Elanco Animal Health, Greenfield, IN) placed subcutaneously in the neck of 
winter anovulatory mares under natural photoperiod. Four non-pregnant mares, 
confirmed to be anovulatory, were assigned randomly to 1 of 2 treatments (2 
mares/treatment): 1) a full estradiol-17β implant (Compudose®; 25.7-mg, s.c.) or 2) a 
precisely cut 1/4 E2 implant (Compudose®; 6.425-mg, s.c.). Two untreated mares 
served as controls and were monitored for direct comparison. Implants were surgically 
inserted subcutaneously and left in place for 4 days. Surgical procedures for placement 
and removal were performed as described below. Following implantation, mares treated 
with both implant sizes developed extensive uterine edema within 48 hours that was 
maintained until implants were removed, as seen on transrectal ultrasonography, 
indicative of elevated circulating E2 [78], whereas no edema was observed in controls. 
3.2.3 Experimental procedures 
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In January, mares were selected for use in the study based on confirmation of 
winter anovulatory status as determined by transrectal ultrasonography performed every 
2 to 3 days for 3 weeks before the start of the experiment. Criteria for confirming the 
anovulatory state included the absence of a CL and no follicle exceeding 29 mm in 
diameter for the 3-week period. A retrospective analysis of plasma concentrations of 
progesterone was also performed in blood samples collected immediately following 
ultrasonography. Body weight (BW) of all mares was estimated using a BW tape based 
on heart girth circumference and BCS was assigned on a 1-9 scale by a single individual. 
During the first week of February, 24 mares confirmed to be anovulatory were 
stratified by age, BCS, and BW and assigned randomly to 1 of 4 treatments (n = 
6/treatment): 1) Control; Silastic® s.c. sham pump, 2) GnRH; native GnRH in saline via 
14-day Alzet® osmotic pump (100 µg/hour, s.c.), 3) GnRH + High E2; GnRH as in 2 
plus Compudose® estradiol-17β implant, (E2 implant; 25.7-mg, s.c.), and 4) GnRH + 
Low E2; GnRH as in 2 and 3 plus 1/4-length E2 implant (6.425-mg, s.c.). Jugular blood 
samples were collected daily for assay of gonadotropins, E2, estrone sulfate, and P4. 
Follicular development and uterine edema were monitored every other day until the 
development of a 30-mm follicle was detected via transrectal ultrasonography. Once a 
30-mm follicle was detected, mares were considered periovulatory and monitored via 
transrectal ultrasonography every day until the development of a 35-mm follicle. Upon 
detection of a 35-mm follicle, mares were treated with human chorionic gonadotropin 
(hCG; Chorulon; MSD Animal Health, Wellington, New Zealand; 2000 IU, I.M.) to 
induce ovulation. Each Alzet pump (model 2ML2; DURECT Corp., Cupertino, CA) was 
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filled with a solution containing GnRH (20 mg/mL; ProsSpec- Tany TechnoGene Ltd., 
Rehovot, Israel) in sterile 0.9% saline.  Pumps had the potential to function for 14 days 
at a pumping rate of 100 µg/hour. All sham pumps consisted of Silastic tubing (Dow 
Corning Corporation, Midland, MI).  
3.2.4 Subcutaneous placement of pumps and implants                                                                                                                                                                                                                                                                                                                                                                                                                                                     
The experiment was initiated in all mares over 2 consecutive days, with Day 0 on 
either February 8 or 9. On Day 0, all mares were placed in a stock and sedated with 
detomidine hydrochloride (Dormosedan; Zoetis U.S., Parsippany, NJ; 20-40 µg/kg BW) 
if necessary. The area at the base of the neck, cranial to the scapula, was clipped and 
prepared for aseptic surgery using an iodophor, followed by povidone iodine solution 
and 70% isopropanol. A local anesthetic (3-5 mL lidocaine hydrochloride) was used and 
a 2-cm skin incision was made at the base of the neck using a sterile no. 10 scalpel. 
Using a blunt surgical instrument, a pocket was formed in which the respective 
treatments were inserted. Mares receiving both E2 and GnRH treatments had 2 separate 
incision sites with at least a 2-cm distance between the two implants. Each incision was 
sutured with #2 synthetic sutures that remained in place for 7 days. Mares failing to 
develop a large follicle and/or to ovulate within the first 14 days had the spent pump 
removed and a second 14-day pump installed on the opposite side of the neck as 
described above.  
3.2.5 Uterine edema 
During each ultrasonographic screening, the uterus was monitored for uterine 
edema as a physiological indicator  of onset of estrogen stimulation [78]. A scoring 
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system described previously was employed (0 = no edema, 1 = minimal edema, 2 = 
marked edema, 3 = maximum normal edema, 4 = excessive edema) [78].  
3.2.6 Estrous behavior 
 Estrous behavior was assessed daily by placing 5 to 6 mares in a pen containing a 
solid-paneled wall adjacent to an intact stallion. Mares were assigned subjective teasing 
scores ranging from 1-4: 1 = physical rejection denoted by kicking or pinning of the 
ears, 2 = slight interest or preference, 3 = interest denoted by vulvar winking, 4 = 
complete breakdown denoted by squatting and/or urination in the presence of the 
stallion. 
3.2.7 Blood sampling 
 Blood samples (10 mL) were collected daily via jugular venipuncture from each 
mare beginning immediately following insertion of osmotic/sham pumps and implants.  
Evacuated tubes (Monojecttm, Covidien, Mansfield, MA) containing disodium 
ethylenediaminetetraacetic acid (EDTA) were used for blood collection. Samples were 
placed on ice until transported to the laboratory for centrifugation (562 x g) at 4°C for 20 
minutes. Plasma was harvested and stored at -20°C until analysis of hormones by RIA. 
3.2.8 GnRH challenge 
Mares that failed to develop a 35-mm follicle and thus were not treated with hCG 
to induce ovulation within the 28-day treatment period (4/6 GnRH + High E2; 5/6 
Controls) were evaluated further by administering a GnRH challenge to assess releasable 
pools of LH and FSH. One day before the challenge, mares were fitted with an 
intravenous jugular catheter (Model J0458B, Jorgensen Laboratories Inc., Loveland, 
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CO) for intensive sampling. Jugular catheters were held in place by #1 non-absorptive 
synthetic suture. At the time of catheter insertion, mares received 30,000 IU of heparin 
(10,000 IU/mL) in 3mL saline to minimize clotting potential. Mares were maintained 
individually in holding pens until the GnRH challenge the next day. Immediately before 
onset of treatment and sampling, 20,000 IU of heparin was administered through the 
catheter.  Gonadotropin-releasing hormone (GnRH; 1 mg) was administered via the 
jugular catheter in 2 mL of 0.9% sterile, physiological saline (GnRH = 0.5 mg/mL). 
Prior to collecting each sample, blood was discarded to avoid heparin contamination. 
Blood samples were collected in 5% EDTA with heparin at -30, 0, 15, 30, 45, 60, 120, 
and 240 minutes in relation to GnRH administration, and placed immediately on ice. 
Catheters were flushed with 4-5 mL of heparinized saline (1000 IU/mL) after each blood 
sample was collected. After the final sample was taken, all jugular catheters were 
removed and insertion sites cleaned with 70% isopropanol. Blood samples were 
immediately placed on ice for transport to the laboratory and centrifuged (562 x g) at 
4°C for 20 minutes. Plasma was stored at -20°C until hormone analysis. 
3.2.9 Hormone analyses 
 Plasma concentrations of progesterone were assayed in triplicate utilizing a 
coated-tube (CT) RIA kit (MP Biomedicals, Santa Ana, CA, products #07-270102 and 
07-270105) validated in this laboratory. Standards provided by the kit were used (0.15, 
0.5, 1.0, 5.0, 20.0 ng/mL) with the addition of two standards (2.0 and 10.0 ng/mL) 
created by serial dilution of the 80-ng/mL kit standard using the 0.0 ng/mL standard as 
the diluent. Prior to assay of unknowns, 3 simultaneous validation curves were 
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performed at 3 incubation times and temperatures to determine optimal incubation 
condition for equine plasma: 1) 37°C water bath for 2 hours as per kit protocol, 2) 4°C 
for 16-20 hours, and 3) room temperature (20° C) for 3 hours. Incubation at 4° C for 16-
20 hours produced a curve with the lowest variance ratio (2.42) and adequate binding 
(48%) compared to the 37° C water bath (variance ratio = 28.6, 61% binding) and room 
temperature (variance ratio = 62.1, 40% binding) incubations, and was therefore utilized 
for assay of unknowns. Samples were assayed in triplicate at a volume of 100 µL and 
pipetted into the coated tubes at room temperature. This was followed by addition of 
radiolabeled tracer (125I-progesterone) at a volume of 1 mL/tube (approximately 40,000 
cpm/tube). Tubes were vortexed briefly using a multitube vortexer and incubated for 16-
20 hours at 4°C. Tubes were decanted and the bound fraction was counted in a gamma 
counter for 1 minute per tube. Recovery of added mass (accuracy) was determined by 
adding known amounts (5.0, and 10.0 ng/mL) of progesterone to a pool of plasma 
obtained from winter anovulatory mares giving an average observed 88.3% recovery. 
Due to consistent underestimation of added mass indicated by the percent recovery of 
added mass, all final values were adjusted accordingly for analysis. The sensitivity was 
0.15 ng/mL and the intra- and interassay coefficients of variation were 4.7% and 4.3%, 
respectively. 
 Plasma concentrations of LH were assayed in duplicate using a double antibody 
RIA validated previously in this laboratory [71,79]. Iodinated tracer, standards and 
references utilized highly-purified equine LH (LH AFP-5130A). Anti-equine LH 
antiserum (AFP-240580) was used at a dilution of 1:120,000. The sensitivity was 0.25 
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ng/mL and the intra- and interassay coefficients of variation were 7.1% and 6.0%, 
respectively. 
Plasma concentrations of FSH were assayed in triplicate with a validated double 
antibody RIA [80] using highly-purified equine FSH (eFSH AFP-8830D) for tracer and 
standards alongside anti-eFSH antiserum (AFP-2062096) at a working dilution of 
1:12,500. The sensitivity was 1.0 ng/mL and the intra- and interassay variation was 6.1% 
and 6.5%, respectively. The highly purified eLH, eFSH and respective antisera were 
provided by Dr. A. F. Parlow, National Hormone and Peptide Program (NHPP), Harbor-
UCLA Research and Education Institute, Los Angeles, CA. 
Plasma concentrations of E2 were determined by RIA using a protocol validated 
previously in bovine serum/plasma [81] and validated for equine plasma in our 
laboratory. Triplicate samples (300 µL) were extracted with 4 mL of HPLC grade 
methyl-tert-butyl ether (MTBE; Fisher Scientific, Hampton, NH) in 16 x 100 mm glass 
tubes for 1 minute using a multitube vortexer. Samples were then frozen in an -80° C 
ultra-low freezer for 20 minutes. The solvent fraction was decanted into corresponding 
12 x 75 mm borosilicate glass tubes and dried at room temperature under industrial-
grade nitrogen gas. The dried extract was rehydrated with 37° C 100 µL 1% BSA (1% 
BSA, 0.01% sodium azide, 0.01 M PO4, and 0.9% NaCl; pH 7.2). The redissolved 
extracts and E2 standards (0.25, 0.5, 1.0, 2.5, 5.0, 7.5, 10.0, 20.0, and 30.0 pg/tube) were 
incubated with 100 µL of estradiol-17β antisera (MP Biomedical, Santa Ana, CA, 
product #07-138216, 1:150,000 vol/vol dilution) for 2 hours on ice at 4° C. Following 
incubation, 125I-estradiol-17β was added to each tube at a volume of 100 µL (MP 
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Biomedical, product #07-138228, adjusted to 5,000 cpm/tube). All tubes were incubated 
at 4° C for 20 hours. Bound and free E2 were separated by adding 0.5 mL of an ice cold 
(4° C) charcoal-dextran suspension and then centrifugation at 3500 rpm for 45 minutes 
at 4°C. The resulting supernatant was decanted into corresponding polypropylene tubes 
and counted in a gamma counter for 1 minute per tube. Cross-reactivities of this 
antibody have been reported as 100% for estradiol-17β, 6.5% for estriol, 5.2% for 
estradiol-17α, 0.6% for estrone, and <0.01% for androstenedione, cholesterol, 
aldosterone, progesterone, and testosterone [81]. The addition of known amounts of 
estradiol-17β to pooled equine plasma (2.5, 5.0, and 50.0 pg/mL) was recovered with an 
average percent recovery of added mass of 108%. Overall percent recovery for 
extraction was 92.3%. Intra- and inter-assay coefficients of variation were 8.4% and 
7.1%, respectively, and sensitivity was 0.25 pg/mL in mare plasma. 
 Plasma estrone sulfate concentrations were determined by RIA performed by Dr. 
Scott Jaques at the Texas A&M University Veterinary Medical Diagnostic Laboratory in 
College Station, TX.   
3.2.10 Statistical analysis 
 Temporal changes in peripheral concentrations of hormones and uterine edema 
were analyzed using a mixed model for repeated measures with main effects of treatment 
and day of treatment using JMP Pro 12.0.1 statistical software [SAS Institute, Cary, 
NC]. The model included random effects of day as the within subject factor, treatment as 
between-subject factor, and mare as the subject. Fixed effects were treatment, day of 
treatment, and the interaction of treatment x day. Repeated effect was day and the 
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subject was mare. If fixed effects were found to be significant (P < 0.05), a Tukey’s 
HSD pair-wise comparison was performed. Analyses of ovulation frequency and 
frequency of behavioral estrus were analyzed via the Fisher Exact Test. Duration of 
behavioral estrus, interval to behavioral estrus, and the interval to ovulation were 
analyzed via one-way ANOVA. Main effects were deemed significant with P ≤ 0.05 and 
a trend toward significance with P ≤ 0.10. 
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3.3. Results 
3.3.1 Uterine edema, teasing behavior and circulating E2 
 The primary objectives of this experiment were to assess pituitary and ovarian 
responses to GnRH and GnRH + E2 treatments. However, other secondary 
characteristics associated with treatments were also evaluated as follows.    
3.3.1.1 Uterine edema  
Similar to edema observed during the preliminary trial, a marked increase in 
uterine edema score was observed on Day 2 after treatment onset in mares in the GnRH 
+ High E2 treatment, with their mean (± SEM) score of 2.33 ± 0.28 greater (P = 0.0052) 
than those in all other treatments (Figure 3.1). By Day 4, mean uterine edema scores in 
the GnRH (2.33 ± 0.28) and GnRH + Low E2 (2.50 ± 0.28) treatments were also 
increased. Edema scores remained greater (P < 0.004) in all GnRH- and GnRH + E2-
treated groups compared to Controls through day 8 (Figure 3.1). Overall mean edema 
scores during the first 14-day GnRH pump/implant period for mares in the GnRH, 
GnRH + Low E2, and GnRH + High E2 groups (1.60 ± 0.12, 1.56 ± 0.12, and 1.77 ± 
0.12, respectively) were greater (P < 0.0001) than those for Controls (0.58 ± 0.12). 
Observable edema dissipated within 48 hours following ovulation/implant-pump 
removal in treated groups. Ovarian-unresponsive mares in the GnRH + High E2 
treatment group failed to maintain a measurable increase in uterine edema past Day 14 
of treatment and did not reestablish edema scores greater than Controls following pump 
replacement on Day 14. 
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Figure 3.1. Uterine edema scores over the first 8 days of treatment. Edema scores range 
from 0 = no edema, 1 = slight edema, 2 = moderate edema, and 3 = normal maximal 
edema [78]. Mares in the GnRH + High E2 group had greater (P < 0.01) uterine edema 
by Day 2 compared to all other treatments. All GnRH-treated groups had greater (P < 
0.004) uterine edema compared to Controls beginning on Day 4 and continuing through 
Day 10 of treatment. Values are least squares means with a pooled SEM of 0.28. 
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3.3.1.2. Teasing scores 
 Observed behavior on teasing with a stallion through the first 14 days of 
treatment is summarized in Table 3.1. All mares (6/6) in the GnRH only group displayed 
estrus (teasing score = 4) by Day 6 of treatment and all GnRH + High E2 mares (6/6) 
displayed estrus by Day 7, with all mares in the latter group maintaining a score of 4 
through Day 12. The mean maximal teasing score for GnRH + Low E2 mares was 3.5 
and was achieved in all mares by Day 6 of treatment. Three of the 6 Control mares 
displayed estrus, but the duration of behavioral estrus was significantly shorter (2.2 days; 
P = 0.0042) compared to all other treatments (≥ 7.3 days; Table 3.1). Despite the 3 
Control mares displaying estrus, the observed largest average follicular diameter was 
markedly smaller (20.8 ± 2.8 mm; P < 0.05) compared to both the GnRH and GnRH + 
Low E2 groups (37.0 ±2.8 mm, 36.1 ±2.8 mm, respectively), in which  6/6 mares in each 
group were induced to ovulate. 
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 Control GnRH GnRH + Low 
E2 
GnRH + High 
E2 
Interval to 
Behavioral 
Estrus (days) 
 
No. 
 
9.0 ± 1.5a 
 
 
3/6a 
 
4.8 ± 1.5b 
 
 
6/6b 
 
4.0 ± 1.5b 
 
 
6/6b 
 
4.5 ± 1.5b 
 
 
6/6b 
Duration of 
Estrus (days) 
 
 
2.2 ± 1.2a 
 
7.3 ± 1.2b 
 
9.2 ± 1.2b 
 
7.7 ± 1.2b 
Frequency of 
Ovulation 
 
0/6c 
 
 
6/6d 
 
6/6d 
 
2/6c,d 
Largest 
Average 
Follicle (mm) 
 
20.8 ± 2.8c 
 
37.0 ± 2.8d 
 
36.1 ± 2.8d 
 
25.9 ± 2.8c 
 
 
Table 3.1. Average interval to full behavioral estrus (teasing score = 4), frequency of 
full behavioral estrus, duration of full behavioral estrus, frequency of ovulation, and 
largest average follicle diameter over the first 14 days of treatment. Averages and 
frequencies with different superscripts differ (a,bP ≤ 0.05); (c,dP < 0.01). 
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3.3.1.3. Plasma concentrations of E2 
 Because of rapid changes in follicle development, ovarian steroidogenesis, and 
occurrence of ovulation in response to GnRH and GnRH + E2 treatments, the first 7 
days of the experiment were used initially to assess potential treatment-induced 
differences in circulating E2. Surprisingly, and in spite of clear changes in uterine edema 
scores, mean plasma concentrations of E2 did not differ (P > 0.1) among groups during 
the first 7 days of treatment (Figure 3.2).  
 
 
Figure 3.2. Least squares mean concentrations of peripheral E2 over the first 7 days of 
treatment. Mean concentrations did not differ. Pooled SEM = 1.55 pg/mL. 
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In ovarian-responsive mares, defined as developing a 35-mm follicle followed by 
induced ovulation with hCG, mean peripheral E2 concentrations were normalized to the 
day of induced ovulation (Day 0, Figure 3.3). During this period, responsive mares (6/6) 
in the GnRH group had greater concentrations of E2 (9.89 ± 1.37 pg/mL, P = 0.02) 
compared to Control mares (3.28 ± 1.37 pg/mL), with maximum concentrations (≥ 10.9 
pg/mL) beginning 3 days prior to ovulation greater (P < 0.05) than those (≤ 3.7 pg/mL) 
observed in Control mares during the same period. Responsive GnRH + Low E2 mares 
(6/6) also exhibited greater circulating E2 (11.5 pg/mL, P = 0.04) on Day 2 before 
ovulation compared to unresponsive Control mares (3.2 pg/mL), whereas the 2 
responsive GnRH + High E2 tended to be greater (6.3 pg/mL, P < 0.1) than Control 
mares on Day 2. Mean circulating E2 prior to ovulation did not differ among responsive 
GnRH, GnRH + Low E2, or GnRH + High E2 mares (Figure 3.3). 
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Figure 3.3. Least squares mean concentrations of peripheral E2 normalized to the day of 
ovulation in responsive mares within each treatment, and in all Controls, which did not 
ovulate (no normalization). Responsive GnRH mares (6/6) had greater mean E2 (P < 
0.05) beginning 3 days before ovulation compared to unresponsive Controls (6/6). 
Responsive GnRH + Low E2 mares (6/6) had greater (P = 0.04) mean E2 on Day 2 
before ovulation compared to unresponsive Controls. Responsive GnRH + High E2 
mares (2/6) tended to have greater mean E2 (P < 0.10) on Day 2 when compared to 
unresponsive Controls. Pooled SEM for GnRH, GnRH + Low E2, and Controls was 1.63 
pg/mL, whereas pooled SEM for GnRH + High E2 was 2.83 pg/mL. 
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3.3.1.4. Plasma concentrations of estrone sulfate 
 
 Previous evidence suggests that exogenous E2 may be efficiently converted into 
estrogen metabolites such as estrone sulfate in mares [82]. In the present study, 
peripheral estrone sulfate paralleled circulating E2. The effects of treatment and 
treatment by day were significant (P = 0.02 and P < 0.0001, respectively; Figure 3.4). 
Unexpectedly, GnRH + High E2 mares had elevated (P = 0.03) baseline estrone sulfate 
(Day 0; 403.7 ± 91.7 pg/mL) compared to GnRH + Low E2 mares, but did not differ 
from GnRH or Control mares (257.4 ± 91.7 pg/mL and 277.6 ± 91.7 pg/mL, 
respectively). On Day 3 of treatment, estrone sulfate in GnRH + Low E2 mares tended 
(P = 0.09; 607.4 ± 91.7 pg/mL) to be greater than in GnRH alone mares (415.5 ± 91.7 
pg/mL), but was not different than in GnRH + High E2 mares (516.1 ± 91.7 pg/mL). By 
Day 6 and coinciding with the development of dominant follicles in responsive mares, 
both GnRH and GnRH + Low E2 groups had greater (P ≤ 0.01; 837.6 ± 91.7 pg/mL and 
1006.0 ± 91.7 pg/mL, respectively) plasma estrone sulfate than Control mares (314.5 ± 
91.7 pg/mL) and tended (P ≤ 0.09) to be greater than GnRH + High E2 mares (504.2 ± 
91.7 pg/mL).  
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Figure 3.4. Mean plasma estrone sulfate during the first 6 days of treatment. The GnRH 
+ High E2 mares had an elevated (P = 0.03; 403.7 pg/mL) baseline on Day 0 compared 
to GnRH + Low E2 mares (209.3 pg/mL). The GnRH + Low E2 group tended (P ≤ 0.09) 
to have greater  mean estrone sulfate on Day 3 compared to GnRH and Control mares. 
Both the GnRH alone and GnRH + Low E2 groups had increased (P < 0.01) mean 
estrone sulfate than the Control group and tended to have greater concentrations (P = 
0.09) than GnRH + High E2 mares. Pooled SEM was 91.7 pg/mL for all groups. 
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3.3.2 Pituitary responses 
3.3.2.1 Plasma concentrations of LH 
 Mean plasma concentrations of LH are shown in Figure 3.5. Mean LH in GnRH, 
GnRH + Low E2, and GnRH + High E2 treatment groups did not differ (P > 0.10, 
Figure 3.5A); therefore, values for these 3 groups were pooled. Beginning on Day 2 and 
continuing through Day 7, mean concentrations of LH increased and were greater (P < 
0.01) in GnRH-treated mares than in Controls (Figure 3.5B).  
Importantly, mean LH in ovarian-responsive (0.72 ± 0.07 ng/mL) and ovarian-
unresponsive (0.93 ± 0.13 ng/mL) GnRH-treated mares did not differ until Day 13, 
coinciding with timing of induced ovulation and removal of osmotic pumps in the 
majority of responsive mares (Figure 3.6). By Day 16, majority of pumps (13/14) had 
been removed in the GnRH-treated, ovarian-responsive mares, and from this point until 
the end of the study on day 28 mean LH in ovarian-unresponsive mares remained above 
(P < 0.03) ovarian-responsive mares (Figure 3.6). In the ovarian-unresponsive (4/6) 
GnRH + High E2 mares (not shown), circulating concentrations of LH was greater (P < 
0.01) than Controls (6/6 mares; 0.27 ± 0.11 ng/mL) beginning on Day 2 and continuing 
for the duration of the 28-day treatment period. A decline (P < 0.05) in concentrations of 
LH was observed in unresponsive GnRH + High E2 mares before replacement of the 
first GnRH osmotic pump on day 14, but values rebounded by day 18 (Figure 3.6). 
 
 
 
 36 
 
 
Figure 3.5. Plasma LH concentrations over initial 7 days of treatment. A.) Mean LH 
concentrations over first 7 days of treatment in all treatment groups (Pooled SEM = 0.6 
ng/mL for all treatment groups). B.) Mean LH concentrations of GnRH- and GnRH + 
E2-treated mares did not differ (P > 0.10) and were therefore pooled for comparison to 
Controls. Pooled least squares mean concentrations of LH in GnRH- and GnRH + E2-
treated mares (n = 18) and in control mares (n = 6) during the first 7 days after treatment 
onset. Concentrations of LH in GnRH-and GnRH + E2-treated mares were greater (P < 
0.01) than Controls from Day 2 through 7. (Pooled SEM = 0.2 ng/mL).  
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Figure 3.6. Least squares mean concentrations of LH in ovarian-responsive and ovarian-
unresponsive GnRH-treated mares over the 28-day experiment. No differences were 
observed between ovarian-responsive and ovarian-unresponsive GnRH-treated mares 
until Day 13, coinciding with onset of ovulations and pump removal in responsive 
mares. Ovarian-unresponsive mares had persistently greater peripheral LH than both 
ovarian-responsive (P ≤ 0.03) and Controls (P ≤ 0.05) for the remainder of treatment. 
Pooled SEM = 0.2 ng/mL. 
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3.3.2.2 Plasma concentrations of FSH 
 
 As observed with circulating LH, mean concentrations of plasma FSH in mares 
in GnRH, GnRH + Low E2, and GnRH + High E2 treatment groups did not differ during 
the first 7 days following treatment initiation. Therefore, values for mares in these 
groups were pooled into a single GnRH-treated group for further analysis. 
Concentrations of FSH increased in GnRH-treated mares and reached a peak (8.4 ± 0.7 
ng/mL; P < 0.05) 24 hours after treatment began relative to Controls (5.4 ± 1.2 ng/mL), 
regardless of ovarian responsiveness (Figure 3.7). Mean FSH concentrations and 
follicular development from representative mares from each treatment group are shown 
in Figure 3.8. The observed peak in FSH dissipated within 48 hours and mean 
concentrations of FSH returned to baseline or lower, depending on ovarian 
responsiveness, in all mares by Day 4 of treatment. 
Similar to ovarian responsive mares treated with GnRH, the FSH peak for 
ovarian-unresponsive mares (4/6 GnRH + High E2 mares) was greater (10.35 ng/mL, P 
= 0.03) than Controls (5.37 ng/mL) at 24 hours after treatment onset (Figure 3.9). 
Following the initial peak, FSH returned to baseline (ovarian-unresponsive) or lower 
(ovarian-responsive) concentrations for the duration of the treatment period. Mean FSH 
concentrations in ovarian-unresponsive mares did not differ (6.42 ± 0.83 ng/mL, P > 0.1) 
from Control (5.56 ± 0.68 ng/mL) or ovarian-responsive mares (4.84 ± 0.36 ng/mL, 
Figure 3.9), following the initial peak.  
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Figure 3.7. Pooled least squares mean concentrations of FSH for all GnRH- and GnRH 
+ E2-treated mares (n = 18/18) and Control mares (n = 6/6) over the initial 7 days after 
treatment initiation. Pooled SEM = 0.8 ng/mL. (* P < 0.05).  
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Figure 3.8: Individual profiles of FSH and follicular development during the 28-day 
treatment period for representative mares in each treatment group, including ovarian 
responsive and unresponsive individuals. 
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Figure 3.8 continued: Individual profiles of FSH and follicular development during the 
28-day treatment period for representative mares in each treatment group, including 
ovarian responsive and unresponsive individuals. 
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Figure 3.9. Least squares mean concentrations of FSH for GnRH- and GnRH + E2-
treated, ovarian-responsive mares (12/12), unresponsive GnRH + High E2 mares (4/6), 
and Control mares (6/6) over the 28-day experiment. Peak concentrations of FSH at 24 
hours after treatment onset for ovarian-unresponsive mares was greater (10.35 ng/mL, P 
= 0.03) than that of Controls (5.37 ng/mL). Pooled SEM for ovarian-responsive, ovarian-
unresponsive, and Control mares were 0.8 ng/mL, 1.1 ng/mL, and 0.6 ng/mL, 
respectively. 
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3.3.2.3 GnRH Challenge 
Mares that failed to develop a 35-mm follicle and thus were not treated with hCG 
to induce ovulation within the 28-day experimental period (n = 4/6 GnRH + High E2; n 
= 5/6 Controls) were evaluated further by administering a GnRH challenge to assess 
releasable pools of LH and FSH. One Control mare developed a 35-mm follicle by Day 
28 of the experiment and was excluded from the GnRH challenge although she was not 
treated with hCG.  
As presented above, mean concentrations of LH for ovarian-unresponsive GnRH 
+ High E2 mares were greater than control mares at the end of the experiment. Thus, 
mean baseline (Time = 0 min; 1.23 ± 0.14 ng/mL) concentrations at onset of the GnRH 
challenge in the former group were greater (P < 0.01) than Controls (0.2 ± 0.12 ng/mL) 
as shown in Figure 3.10A and remained greater (P = 0.0009; 1.33 ± 0.09 ng/mL) than 
Control mares (0.64 ± 0.08 ng/mL) throughout the post-GnRH sampling period.  
Because of the differing baseline, mean concentrations were transformed to a percent of 
Time -15 min values as presented in Figure 3.10B. Beginning 15 minutes after bolus 
GnRH injection, percent change in mean LH in Controls increased (P = 0.01) and 
remained elevated above GnRH + High E2 mares and the pre-treatment mean until the 
end of sampling at 240 minutes. Treatment with GnRH had no effect on circulating 
concentrations of LH in the GnRH + High E2 mares (Figures 3.10A and Figure 3.10B). 
44 
 Unlike mean LH, baseline concentrations of FSH in GnRH + High E2 and 
Control mares did not differ.  Treatment with GnRH at Time 0 resulted in increased 
concentrations (≥ 7.86 ng/mL; P < 0.0001) of FSH in Controls compared to GnRH + 
High E2 mares (3.76 ng/mL) beginning 15 minutes after and continuing through 240 
minutes.  As noted earlier, mean concentrations of FSH did not change in GnRH + 
High E2 mares after GnRH treatment (Figure 3.11). 
 45 
 
 
Figure 3.10. Plasma LH response to bolus, intravenous injection of 1 mg GnRH in 
ovarian-unresponsive GnRH + High E2 mares (n = 4/6) and Control mares (n = 5/6). A.) 
Least squares mean LH beginning 30 min before bolus GnRH injection (Time = 0) and 
lasting until 240 minutes post-injection. B.) Least squares mean concentrations of LH 
presented as a percent of Time -15 minute values for ovarian-unresponsive GnRH + 
High E2 mares (4/6) and Control mares (5/6) due to elevated  (P < 0.01) baseline in 
GnRH + High E2 mares. Control mares tended to have a greater percent change (P < 
0.07) in mean LH compared to Controls beginning 15 minutes after GnRH injection and 
lasting until 240 minutes post-injection. Mean values in GnRH + High E2 mares did not 
differ from baseline after GnRH challenge. Pooled SEM for GnRH + High E2 mares and 
Control mares were 0.12 ng/mL and 0.14 ng/mL, respectively. 
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Figure 3.11. Least squares mean concentrations of FSH beginning 30 min before and 
continuing for 240 minutes after bolus intravenous injection of GnRH (Time 0) in 
Control mares and ovarian-unresponsive mares in the GnRH + High E2 group. 
Concentrations of FSH in Control mares treated with GnRH were greater (P < 0.01) than 
the pre-treatment baseline and greater than the GnRH + High E2 group which did not 
change from baseline. Pooled SEM for GnRH + High E2 and Control mares was 1.25 
ng/mL and 1.12 ng/mL, respectively. 
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3.3.3 Ovarian responses 
 
3.3.3.1 Follicular development and ovulation 
 Ovarian characteristics are presented in Table 3.2. Baseline follicular diameter 
was not different amongst treatment group (P > 0.1; data not shown). None of the 
Control mares (0/6) were induced to ovulate within the 28-day treatment period and only 
1 developed a 35-mm follicle, which occurred on Day 28.  However, within the first 15 
days of treatment onset, 5/6 GnRH and 6/6 GnRH + Low E2 mares had developed a 35-
mm follicle and were induced to ovulate.  Only 2/6 GnRH + High E2 mares developed a 
35-mm follicle, both by Day 9, and were induced to ovulate by Day 15 of treatment. To 
facilitate statistical analysis, mares that did not ovulate within the 28-day treatment 
window were assigned an arbitrary interval to ovulation of 28 days. Frequency of 
development of a 35-mm follicle and ovulation were greater in GnRH and GnRH + Low 
E2 than in Controls and intervals to these end-points were markedly reduced compared 
to Controls (Table 3.2). The lifespan of induced corpora lutea and average interval to the 
next pre-ovulatory follicle was not different among ovulatory mares regardless of 
treatment (data not shown). 
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Table 3.2. Average interval to 35-mm follicular development, interval to ovulation, 
number of ovulatory mares per treatment, and average date to first ovulation in groups 
with responsive mares. Means within rows with different superscripts differ (a,bP < 
0.015), (c,d P < 0.002) 
 
 Control GnRH 
GnRH+Low 
E2 GnRH+High E2 
Interval to 
35 mm 
follicle, d 
 
No. mares 
28.0 
 
1/6a 
11.7 
 
6/6b 
8.7 
 
6/6b 
21.7 
 
2/6a,b 
Interval to 
ovulation, d 
 
No. mares 
28 
 
0/6c 
13.7 ± 7.2 
 
6/6d 
10.7 ± 2.9 
 
6/6d 
23.7± 9.8 
 
2/6c,d 
Avg. date 
First 
ovulation 
N/A Feb. 22 Feb.21 March 3 
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3.3.3.2 Luteal progesterone 
 Post-ovulatory concentrations of plasma progesterone did not differ among 
ovarian-responsive mares in GnRH (6/6), GnRH + Low E2 (6/6) and GnRH + High E2 
(2/6) treatment groups (Figure 3.13; P = 0.11). Average functional CL lifespan, defined 
as concentrations of progesterone remaining above 1.0 ng/mL, did not differ among 
GnRH (14.8 days), GnRH + Low E2 (14.0 days), and GnRH + High E2 (13.5 days) 
treatment groups. 
 
 
 
Figure 3.12. Mean peripheral P4 relative to day of ovulation (Day 0) in ovulatory GnRH 
alone (6/6), GnRH + Low E2 (6/6) and GnRH + High E2 (2/6) mares. Pooled SEM for 
GnRH alone and GnRH + Low E2 is 0.58 ng/mL, pooled SEM for GnRH + High E2 is 
1.01 ng/mL. 
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3.4. Discussion 
 Based on findings in the current experiment, continuous treatment of winter 
anovulatory mares with E2 using a subcutaneous estradiol implant, designed to create 
either a relatively low (1/4 implant) or high (full implant) estrogenic environment, did 
not enhance gonadotropic responses to continuous treatment with GnRH. Similarly, 
there was no enhancement of ovarian responses, although this interpretation is based on 
a relatively small number of observations for this type of variable.  The E2 source 
utilized in this study (Compudose implant), when placed subcutaneously into the ear of 
cattle, creates mean E2 concentrations of approximately 100 pg/mL over a long duration 
[83] and creates growth-promoting effects in that species for at least 200 days. Although 
the relative efficacy of these implants for elevating plasma E2 in mares has not been 
studied previously, the basic concepts associated with elution of steroid hormones from 
Silastic rubber implants administered subcutaneously has been widely reported in 
livestock species [84-87]. In our preliminary experiments, both the 1/4-sized and full 
implants alone resulted in significant to extensive uterine edema in all mares examined 
within 24-48 hours after implant insertion. However, despite a similar observation in the 
current experiment, peripheral plasma E2 was not increased in a dose-related fashion 
relative to Controls or to mares treated with only GnRH.  
It has been well established that mares quickly convert circulating E2 into 
conjugated estrogens, including estrone sulfate, with plasma concentrations of 
conjugates measuring 100-fold greater than plasma E2 [88]. The relative efficiency of 
this conversion, especially in response to exogenous treatment with E2, has not been 
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well-defined. A recent study that evaluated the effects of varying doses (2.5 mg to 10 
mg) of estradiol benzoate in cycling mares demonstrated that mean concentrations of 
circulating E2 never exceeded 14 pg/mL [82] and thus were not dose-related. To the 
contrary, the increase in estrone sulfate ranged from 200 to 600 pg/mL, and was dose-
dependent [82], suggesting rapid conversion of exogenous E2 to a metabolic conjugate 
[89]. In the current experiment, we also assayed a selected number of samples for 
estrone sulfate using RIA. Estrone sulfate in these samples did not rapidly increase as 
expected in the GnRH + E2 treatments after treatment onset. However, estrone sulfate 
concentrations rose markedly by Day 6 in GnRH and GnRH + Low E2 mares, 
coinciding with the development of dominant follicles in these responsive mares. 
Though the conversion of estrone sulfate occurs as previously described [82,83,88,89], it 
was not associated with the onset of E2 treatment. However, the E2 eluted from the 
implants could have been converted immediately into metabolites other than estrone 
sulfate, such as estrone, equilin, estrone-3-glucuronide, or estradiol-3-sulfate [88], 
accounting for the marked uterine edema observed by Day 2 of treatment in the mares 
receiving the full E2 implant. Unfortunately, peripheral E2 metabolites other than 
estrone sulfate were not measured in this experiment. It is possible that the Compudose 
E2 implants may not effectively stimulate E2 above basal concentrations in the winter 
anovulatory mare and, therefore, the conversion into estrone sulfate is not discernable 
until a dominant follicle is present. 
 Similar to previous studies utilizing subcutaneous osmotic pumps to deliver 
native GnRH to winter anovulatory mares, continuous infusion stimulated increased 
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secretion of peripheral LH within 48 hours after treatment began [58,59]. Circulating 
concentrations of LH remained well above control values until pump removal following 
confirmed ovulation or at the end of the 28-day treatment. Both maximal and mean 
concentrations of LH were unrelated to ovarian responsiveness or baseline follicular 
diameter in the current study (data not shown), which is similar to previous observations 
reported from our laboratory [59]. The majority of GnRH-treated mares had developed a 
35-mm follicle and were induced to ovulate within the first 15 days after treatment onset 
and all but one responsive mare (GnRH alone) had ovulated by the first week in March, 
regardless of E2 treatment. The timing of and intervals to first ovulation in this study 
correspond to those reported in previous work involving the use of native GnRH [55-
57,80]. Although only 2 of 6 mares in the GnRH + High E2 group developed a 35-mm 
follicle and were induced to ovulate, the lack of response in the remaining mares (4/6) 
could not be related to any observed differences in secretion of LH or FSH, or any other 
feature that would differentiate them from the 10-15% of winter anovulatory mares that 
historically fail to respond to similar treatments [58-60,71].  In a previous study reported 
from this laboratory, twice daily injections of E2 in corn oil alone failed to increase 
mean circulating LH compared to controls during a 14-day treatment period in winter 
anovulatory mares [71]. However, twice daily E2 injections combined with continuous 
GnRH did enhance (0.5 to 0.8 ng/mL increases; P < 0.05) pituitary secretion of LH 
compared to continuous GnRH treatment only. Unfortunately, circulating E2 was not 
measured in that study. Therefore, the lack of a dose-related increase in either plasma E2 
or estrone sulfate in the current study in response to a 1/4- or full-size Compudose 
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implant suggests that the implants failed to elute expected amounts of E2. As a result, 
neither plasma values of E2 nor estrone sulfate exceeded those expected and observed in 
association with the dominant follicles that developed in the majority (14/18) of GnRH 
and GnRH + E2-treated mares.   
The equine pituitary has a limited number of monohormonal gonadotropes for 
either LH or FSH (9.7% during the winter anovulatory period, 22.5% during the 
breeding season), while the majority of gonadotropes are bihormonal [90]. Though not 
considered the limiting factor in winter anovulation [12,91], it was expected that FSH-
secreting gonadotropes would respond similarly to LH-secreting gonadotropes and lead 
to a comparable pattern of secretion in response to continuous infusion of GnRH until 
development of a large, deviated follicle. Instead, FSH exhibited an acute peak 
approximately 24 hour after treatment onset and then declined abruptly. Acute increases 
in FSH due to continuous infusion of GnRH via an indwelling catheter have previously 
been reported followed by a subsequent decline within 5 to 7 days, depending on dose 
[55]. The rapid decline was attributed to possible increasing concentrations of intra-
follicular E2 and inhibin, since all GnRH-treated mares in that experiment ovulated by 
Day 15 [55]. However, authors were unable to confirm the same type of response in a 
second experiment [56]. Similar to changes in LH, concentrations of FSH were much 
greater in response to hourly i.v. injections of GnRH [55,56] when compared to 
subcutaneous treatment as shown in the study herein. In the current study, FSH declined 
to baseline (ovarian-unresponsive mares) or below (ovarian-responsive mares) by Day 4 
of treatment and did not rebound while pumps remained in situ. Since the majority of 
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responsive mares had developed a 35-mm follicle well before Day 15 (93%), the decline 
in FSH in these mares could be attributed to inhibitory feedback of inhibin from the 
large follicle, similar to that suggested by Johnson et al. [55]. However, the consistency 
and timing of this response, especially in unresponsive mares, is more in keeping with 
differentially-controlled desensitization of FSHβ synthesis and secretion as compared to 
LH.  
 During the luteal phase in cycling mares, continuous infusion of GnRH has been 
shown to create rapid, episodic release of LH similar to that seen during the follicular 
phase [58].  While this has not been demonstrated to occur in anovulatory mares, the 
continuous mode of GnRH exposure may mimic the rapid, follicular phase pulses (1 
pulse/hour) of GnRH known to favor LH synthesis and release [2]. In contrast, a slow 
frequency of GnRH pulses (1 pulse/3-4 hours) favors FSH synthesis and release [2]. 
Therefore, the continuous subcutaneous infusion of GnRH as described here and 
previously, although not physiologically optimal, may favor synthesis and secretion of 
LH while maximally down-regulating FSH synthesis and secretion. In addition, the 
initial stimulation with exogenous GnRH may exhaust the releasable pools of FSH 
already existent within the pituitary. The initial stimulation by GnRH may be sufficient 
for immediate FSH secretion, but may not stimulate transcription necessary for 
additional FSH synthesis. In sheep, it has been reported that a greater proportion of 
releasable FSH is released per day and is more closely related to the rate of synthesis 
than is LH [92,93]. Thus, Chappel et al [92] suggested it may be easier to exhaust the 
releasable pool of FSH than LH in response to repeated GnRH stimulation. If this holds 
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true in mares, it is possible that the initial observed peak in FSH reflects the releasable 
pool of FSH existent within the pituitary at the time of treatment onset, which becomes 
rapidly depleted. Once the existent pool is depleted, further GnRH stimulation causes 
immediate but indiscernible release of FSH without observable increases in the baseline 
in unresponsive mares.  
Because ovarian-unresponsive mares (Controls n= 5/6; GnRH + High E2 n = 4/6) 
had not ovulated or resumed ovarian cyclicity during the 28-day experiment, we used 
them to contrast total releasable pools of LH and FSH in mares either treated (GnRH + 
High E2) or untreated with GnRH during that period.  Modest but measurable increases 
in both gonadotropins relative to pre-treatment baselines were observed in Control mares 
but not in GnRH + High E2 mares.  As noted previously, the pretreatment baseline for 
LH, but not FSH, was elevated in the GnRH-treated mares compared to Controls. 
Collectively, these observations suggest that both LH- and FSH-secreting gonadotropes 
had been maximally stimulated with continuous GnRH treatment and were unable to 
respond further. The basis of this unresponsiveness, as discussed above, could differ 
between the two cell types but, due to the limited population of monohormonal 
gonadotropes, is likely related to either GnRH receptor down-regulation and/or depletion 
of releasable pools as a result of the 28-day treatment. In contrast, Control mares had 
measurable but modest increases in LH release in keeping with near depletion of this 
gonadotropin in seasonally anovulatory mares during the winter [4,12]. However, release 
of FSH in response to GnRH challenge was much more substantial than for LH and 
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agrees with the concept that FSH synthesis and release is not significantly hindered 
during the anovulatory season [12].  
As indicated earlier, follicular responses in this study were unrelated to baseline 
follicular diameters, similar to that observed in our previous report [59]. Given the 
patterns of LH and FSH release observed in response to GnRH, there was no basis to 
attribute lack of ovarian responsiveness to limitations in secretion of LH. With respect to 
FSH, acute changes in response to GnRH were essentially identical across treatments. 
However, once the opportunity for follicle selection had passed in connection with the 
initial FSH peak, FSH secretion patterns were unremarkable in unresponsive mares for 
the balance of treatment and additional peaks of FSH in association with growth of a 
dominant follicle were not observed. Therefore, we remain unable to explain the basis of 
the 10-15% ovarian unresponsiveness observed herein and in previous studies reported 
from our laboratory and others [57-60,71].  
However, one factor potentially regulating the follicular response to GnRH is the 
ovarian intra-follicular environment itself. Deviation is said to occur when the future 
dominant follicle of mares is approximately 23 mm in diameter [94,95] and as FSH is 
declining [96]. Recent studies have pointed to IGF-1 as being a sensitizer to the 
declining FSH surge [97]. Supporting this theory, IGF-1 concentrations increase 1 day 
prior to deviation in ovulatory follicular waves [98] and regulate the production of 
inhibin-A and activin-A [99]. When subordinate follicles were injected with 
pharmacologic doses of IGF-1, they become dominant follicles in a majority of mares 
[99,100]. Conversely, dominant follicles injected with IGF binding proteins ceased 
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follicular growth and follicles soon became atretic [101]. In the current study, the four 
ovarian-unresponsive, GnRH + High E2-treated mares began a follicular wave within 48 
hours of the FSH peak, but follicle diameters did not exceed 25 mm and regressed. Thus, 
we speculate that ovarian-unresponsive mares may have inadequate intra-follicular IGF-
1 concentrations or greater concentrations of IGF binding proteins, thereby hindering 
sensitivity to FSH and preventing further follicular growth and ovulatory responsiveness.  
Based off these findings, future investigations regarding the intra-follicular 
environment and its feedback on the pituitary of responsive and unresponsive mares 
during GnRH infusion could contribute to our understanding of this phenomenon. 
Regarding the E2 implants used simultaneously with native GnRH infusion in the 
current study, investigation into the circulating concentrations of metabolites other than 
estrone sulfate would be valuable to further ascertain the effectiveness of the implants in 
the equine as it relates to follicular response. 
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IV. CONCLUSIONS 
The study herein furthers the understanding of the pituitary-ovarian effects of 
continuous infusion of subcutaneous, native GnRH in the winter anovulatory mare. In a 
previous experiment reported from this laboratory [71], twice daily intramuscular 
injections of E2 enhanced the response of winter anovulatory mares to continuous GnRH 
treatment over a 14-day period. In the current study, injected E2 was replaced by the 
continuous presence of either a small (1/4-size) or large (full-size) E2-containing implant 
(Compudose®). Based on the results of this experiment, neither implant enhanced 
pituitary responses to GnRH.  This is in spite of the fact that mares exposed to a full 
implant exhibited normal, maximal uterine edema within 48 hours of treatment onset. 
However, mean E2 concentrations did not exceed 22 pg/mL, and both plasma E2 and 
estrone sulfate concentrations mirrored increases in E2 typically expected to occur in 
association with a large, dominant follicle, such as occurred in this study. Taken 
together, and in spite of the presence of a reliable estrogenic biomarker (uterine edema), 
these data question the effectiveness of Silastic implants such as those used here to 
achieve graded increases in E2 dose. However, it cannot be ignored that E2 eluted from 
the E2 implant could be metabolized immediately into an active metabolite other than 
estrone sulfate. Unfortunately, no other metabolites were assayed for in the current 
study. 
In the current experiment, and similar to that reported previously from this 
laboratory [58,59], mean LH did not differ between ovarian-responsive (developed a 35-
mm follicle and were induced to ovulate) and ovarian-unresponsive mares. Although not 
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examined previously, the response of FSH-secreting gonadotropes to continuous, 
subcutaneous treatment with native GnRH did not mimic that of LH. Instead, an acute 
increase in plasma FSH that peaked within 48 hours, then declined to baseline within 4 
days, was observed. This pattern, although commonly observed in response to the 
feedback effects of estradiol and other components of a large, dominant follicle, seemed 
unrelated to such an explanation in the current study. All mares, regardless of whether 
they developed a large follicle or not, had the same FSH secretion pattern in response to 
GnRH treatment. Therefore, it appears that the continuous exposure of FSH-secreting 
gonadotropes to native GnRH, at the rate administered in this study, results in down-
regulation of the GnRH receptor as it relates to FSH synthesis.  Collectively, the failure 
of winter anovulatory mares to respond to continuous infusion of native GnRH could not 
be attributed to differences in the magnitude or pattern of LH and FSH secretion 
compared to responsive mares. A GnRH challenge administered to ovarian-unresponsive 
GnRH + High E2 mares and Control mares revealed an inability of the former to release 
additional gonadotropin whereas controls, not exposed previously to continuous GnRH 
treatment, did exhibit a measurable increase in both LH and FSH. The latter is indicative 
of the small releasable pools known to exist in winter anovulatory mares. The failure to 
release additional gonadotropins in the unresponsive GnRH + High E2 mares suggests a 
maximal stimulation of pituitary gonadotropes. In the equine scenario, this is manifested 
by a chronically elevated but subdued LH baseline capable of stimulating follicle growth 
but unable to respond to further stimulation because of receptor down-regulation. In the 
case of FSH, maximal stimulation was characterized by an acute, short-lived peak in 
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FSH release followed by a return to baseline, also indicative of receptor down-regulation 
or a small releasable pool of FSH within the pituitary. Taken together, these responses 
suggest that the chronic infusion of GnRH favors the synthesis and secretion of LH 
while differentially down-regulating FSH synthesis and secretion at a much faster pace.    
It should be noted that a follicular wave was stimulated in all mares treated with GnRH 
regardless of E2 treatment. However, follicular diameter in unresponsive GnRH-treated 
mares did not exceed 25-mm and regressed, indicating that conditions necessary for 
follicular deviation were not present. Further investigations into this phenomenon are 
warranted.  
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APPENDIX 
 
Methodology 
 
Equine progesterone (P4) RIA 
1. Iodinated Product: [125I]-Progesterone (from MP Biomedical CT kit #07-270102 
and #07-270105) 
 
2. Antibody: Coated tube anti-progesterone (MP Biomedical, CT kit #07-270102 
and #07-270105)  
 
3. Standards (stds): kit provided standards (0.15 – 20.0 ng/ml)  
 
a. Two additional standards were made: 2.0 ng/ml and 10.0 ng/ml by 
serially diluting the kit-provided 80.0 ng/ml standard with the excess 0.0 
ng/ml kit provided standard.  
 
4. References (refs): Progesterone added to winter anovulatory equine plasma (1.0, 
5.0, and 10.0 ng/ml) 
 
5. Procedure:  
 
Day 1: 
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a) Pipette 100 µL of each STANDARD, SAMPLE and CONTROL into its 
respective coated tube. 
 
b) When all samples have been pipetted, add 1.0 mL of PROGESTERONE-125 
to all tubes and vortex briefly. 
 
c) Incubate all tubes: Incubate at 4° for 16-24 hours 
 
Day 2: 
d) Aspirate or decant the contents of the tubes in the same order as pipetted. (If 
decanting, blot the tube on absorbent paper before turning upright.) 
 
Decanting procedure: Have a basin for decanted liquid as well as a 
disposable, absorbent blotting material ready. Using a foam 12x75mm 
tube holder (holds 100 tubes/holder), place all tubes besides TC into the 
holder. In a quick fluid motion, flip the holder with the tubes over the 
basin and allow liquid to empty from tubes. Immediately blot the tubes on 
the absorbent material and then invert them upright.  
 
e) Count the tubes in a gamma counter 
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Equine luteinizing hormone (LH) RIA 
1. Iodinated Product: Iodination grade eLH (AFP-5130A) 
2. Antibody: Anti-equine LH (AFP-240580). Dilution 1:120,000 
3. Standards (stds): Iodination grade equine LH (AFP-5130A; 0.1 – 20.0 ng/mL) 
4. References (ref): equine LH added to equine serum  
5. RIA Procedure: 
A. Day 1: Begin Assay 
1. NSB – 500 µL of 1% PBS-EW (egg white) 
2. Std – 500 µL of 1% PBS-EW 
3. Stds – 200 µL std + 300 µL of 1% PBS-EW 
4. Ref – 200 µL ref + 300 µL of 1% PBS-EW 
5. Unknown – 200 µL unknown sample + 300 µL of 1% PBS-EW 
6. Pipette 200 µL of PBS-EDTA + 1:400 NRS without primary antibody            
into NSB tubes only 
7. Pipette 200 µL of anti-eLH (diluted in PBS-EDTA + 1:400 NRS) into all 
tubes except NSB and TC tubes 
8. Pipette 100 µL 125I-eLH (20,000 cpm/100 µL diluted in 1% PBS-EW) 
into all tubes 
9. Vortex tubes briefly and incubate for 24 h at 4°C 
B. Day 2: Add Second Antibody 
1. Pipette 200 µL of Sheep-anti-rabbit gamma globulin (SARGG; 2nd Ab) 
diluted in PBS-EDTA without NRS into all tubes except TC tubes 
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2. Vortex tubes briefly and incubate for 48-72 h at 4°C 
C. Day 4: Pour Off Assay 
1. Add 3 mL ice cold PBS (0.01 M; pH 7.0) to all test tubes except TC tubes 
2. Centrifuge tubes for 1 h at 4°C at 3600 rpm 
3. Decant supernatant 
4. Count radioactivity of each tube using a gamma counter 
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Equine follicle-stimulating hormone (FSH) RIA 
 
1. Iodinated Product: Iodination grade eFSH (AFP-5022B) 
2. Antibody: Anti-equine FSH (AFP-2062096). Dilution 1:12,500 
3. Standards (stds): Iodination grade eFSH (AFP-5022B; 0.5 – 25 ng/mL) 
4. References (ref): eFSH added to equine plasma (2.0 and 8.0 ng/ml) 
5. RIA procedure: 
A. Day 1: Begin Assay 
1. NSB - 500 µL of 1% PBS-EW (egg white). 
2. 0 Std - 500 µL of 1% PBS-EW. 
3. Stds - 200 µL std + 300 µL of 1% PBS-EW. 
4. Ref - 200 µL ref + 300 µL of 1% PBS-EW. 
5. Unknown - 200 µL sample + 300 µL of 1% PBS-EW. 
6. Pipette 200 µL of PBS-EDTA + 1:400 NRS without primary antibody 
into NSB tubes only. 
7. Pipette 200 µL of anti-eFSH (diluted in PBS-EDTA + 1:400 NRS) into 
all tubes except NSB and TC tubes. 
8. Vortex tubes briefly and incubate for 1 h at room temperature. 
9. Pipette 100 µl 125I-eFSH (20,000cpm/100 µl diluted in 0.1% PBS-EW) 
to all tubes. 
10. Vortex tubes briefly and incubate for 24 h at 4°C. 
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B. Day 2: Add Second Antibody 
1. Keep all test tubes and reagents on ice during all procedures. 
2. Pipette 200 µl of Sheep-anti-rabbit gamma globulin (SARGG; 2nd Ab) 
diluted in PBS-EDTA without NRS into all tubes except TC tubes. 
3. 3. Vortex tubes briefly and place in refrigerator for 48-72 h at 4°C. 
 
C. Day 4: Take Off Assay 
1. Keep all test tubes and reagents on ice during all procedures. 
2. Add 3.0 mL ice cold PBS (0.01 M; pH 7.0) to all tubes except TC tubes. 
3. Centrifuge tubes for 1 h at 4°C at 3600 rpm. 
4. Decant supernatant. 
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Equine estradiol-17β (E2) RIA 
1. Iodinated Product: [125I]-estradiol-17β (conjugated to 3-position, MP Biomedical 
product #07-138228) 
 
2. Antibody: Anti-estradiol-17β (conjugated to 3-position, MP Biomedical #07-
138216). Diluted to 1:150,000 
 
3. Extraction solvent: Methyl-tert-butyl-ether (MTBE, HPLC grade, Fisher Scientific) 
 
4. Standards (stds): Constructed from 50.0 ng/ml estradiol-17β in methanol (MeOH). 
Various volumes (described below) pipetted into 12 x 75 mm borosilicate glass tubes 
dried down and rehydrated (1.25 – 150.0 pg/ml) 
 
5. References (refs): Estradiol-17β (E2) added to pooled equine plasma. A calculated 
amount of 5,000 pg/ml E2 in MeOH was dried down and rehydrated with equine 
plasma to constitute a 100 pg/ml reference (high ref). The high ref was serially 
diluted with equine plasma to create 2.5, 5.0, and 50.0 pg/ml references. A baseline 
(no added mass) ref was included in each assay. 
 
6. Extraction Procedure 
 
I. Tracer Preparation – Prepare prior to recovery estimates (Using “bulk TE tracer”) 
 87 
1. Dilute bulk stock tracer as per MP Biomedical instructions to yield a 1:300 stock 
solution. 
2. In triplicate, count 100 µL of 1:300 stock.  
3. Calculate the needed amount of tracer for the assay (100 µL/tube of 5,000 
cpm/100 µL tracer).  
4. Using only what is needed for the current assay, dilute a portion of the 1:300 
stock tracer to obtain 5,000 cpm/100 µL using the equation below. 
 
(cpm/.1 ml in 1:300)x = (5,000 cpm/.1 ml)(ml of tracer needed for assay) 
 
II. Recovery Estimates – Prepare at least 30 min prior to extraction 
1. Pipette 1500 cpm 125I-estradiol (diluted prior to assay) into charcoal-stripped (or 
baseline) plasma/serum of same volume as unknowns/references. 
a. Keep volume of tracer per ml low (25-100 µl) 
b. Mix and allow to equilibrate at 4°C for at least 30 minutes before 
extracting 
c. Make 3 total count recoveries (TCR) using 12x75mm culture tubes using 
same volume of tracer (25-100 µl) used for recovery estimates 
i. These will not undergo the extraction process – keep with TC’s 
 
III. Extraction Set-Up 
 88 
1. Pipette 0.3 ml of unknown and reference samples into 16x100 mm Pyrex tubes in 
duplicate.  
2. Add 4 ml of methyl-tert-butyl ether (MtBE, HPLC grade) to each reference, 
unknown, blank and recovery-estimate tube. 
3. Vortex for 1 minute using multi-tube vortexer or for 30-40 minutes using an end-
to-end shaker. 
 
IV. Separating/harvesting solvent from extracted serum/plasma and blank tubes 
1. Following vortexing allow tubes to sit upright at room temperature for 15 
minutes to allow phases to separate. 
2. Place tubes in ultra-low freezer (-80°C) for 20 minutes or as long as required for 
the plasma/serum to freeze solid.  
a. Alternatively, a dry-ice/methanol bath or liquid nitrogen can be employed 
to accomplish this quickly. 
3. Remove frozen samples, place on ice, and quickly decant the supernatant into 
12x75mm borosilicate assay tubes to avoid thawing of plasma/serum. 
a. NOTE: It is recommended to only extract one rack (~72 tubes) at one 
time to avoid thawing of serum during this procedure (MMO, June 2017) 
 
V. Drying extracts 
1. Dry references, unknowns and blanks to complete dryness under air in the hood. 
Samples can be heated to 37°C if desired using a heating block. Do not over-dry 
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a. KLCT403 – Compressed N2 can be fed into the drying apparatus under 
the fume hood in KLCT401. 
2. Extracts from recovery estimates should be dried partially to minimize the 
chance of spillage (0.5 – 1 ml) but need not be dried completely. Rehydrate with 
100 µl 1% BSA. 
a. Set aside with TCR and TC after this step 
 
VI. Rehyrdation of extracts 
1. Rehydrate references and unknowns with 37°C assay buffer (1% BSA) to bring 
to volume of 100 µl and vortex. Cover and place in refrigerator until ready to 
proceed with assay. 
 
VII. Standard Curve Tubes  
1. Using 12x75mm borosilicate glass tubes, pipette 4 ml MTBE into the standard 
curve tubes (#10-39). Do not expose NSB tubes to MTBE. 
2. Using the drying rack, dry down standard tubes to complete dryness. 
3. Once all other extracted tubes are dried and rehydrated, pipette the following 
volumes of 50 pg/ml E2 in methanol into the respective standard tubes: 
 
i. 1.25 pg/ml  5 µl 
ii. 2.50 pg/ml  10 µl 
iii. 5.00 pg/ml  20 µl 
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iv. 12.5 pg/ml  50 µl 
v. 25.0 pg/ml  100 µl 
vi. 37.5 pg/ml  150 µl 
vii. 50.0 pg/ml  200 µl 
viii. 100.0 pg/ml  400 µl 
ix. 150.0 pg/ml  600 µl 
 
4. Once completely dried, rehydrate with 100 µl warm (37 °C) 1% BSA. 
 
 
7. RIA Procedure 
I. Assay Set-Up 
A. Label assay sheets and number the tubes (12x75 mm borosilicate glass 
tubes and 12x75mm plastic recipient tubes) and counting vials (plastic 
vials; 7 ml) as follows): 
Tubes:    Tube Numbers: 
a) 5 TC tubes   1-5 
b) 4 NSB   6-9 
c) 3, 0 STD   10-12 
d) Triplicate for each 
     standard    13-39 
e) 3 Baseline   40-42 
 91 
e) 3 Lowest ref  43-45 
f) 3 Low ref   46-48 
g) 3 Mid ref   49-51 
h) 3 High ref   52-54 
i) 3 Blanks   55-57 
j) 3 Recoveries  58-60 
k) 3 TCR   61-63 
l) Triplicate unknowns  
 
II. Day 1 
A. Pipette the following volumes of 50 pg/ml E2 in methanol for each 
respective standard tube: 
1) 1.25 pg/ml  5 µl 
2) 2.50 pg/ml  10 µl 
3) 5.00 pg/ml  20 µl 
4) 12.5 pg/ml  50 µl 
5) 25.0 pg/ml  100 µl 
6) 37.5 pg/ml  150 µl 
7) 50.0 pg/ml  200 µl 
8) 100.0 pg/ml  400 µl 
9) 150.0 pg/ml  600 µl 
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As with extractions, dry-down the tubes completely using the drying rack 
under compressed nitrogen. Do not allow the tubes to over-dry. 
Rehydrate each tube with 100 µl warm (37°C) 1% BSA. 
 
B. Pipette the following into each tube: 
1) NSB   200 µl 0.1% PBS-Gel 
2) 0 Standard  100 µl 1% BSA 
3) STD’s  Respective E2-methanol volume dried-
down 
Rehyrdated with 100 µl 1% BSA 
C. Once the tubes containing plasma/serum extracts are dried, bring to assay 
volume (rehydrate) of 100 µl using warm 1% BSA and vortex briefly to 
re-dissolve estradiol dried to the walls of the tubes. 
D. Pipette 100 µl E2 antiserum (1st antibody) into all tubes except NSB’s, 
recoveries, and TC recoveries (TCR). Working dilution of antiserum is 
to be determined in advance of the assay.  
E. Incubate for 1 hr on ice in the refrigerator at 4°C before adding tracer 
F. Pipette 100 µl 125I-E2 (5000-6000 cmp/100 µl) into all tubes including TC 
vials. 
1) Pre-dilute the TE tracer prior to assay 
G. Vortex tubes briefly, cover with aluminum foil and incubate for approx.. 
20 hours at 4°C. 
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III. Day 2 
 
A. Add 1.0 ml of ice cold Charcoal-Dextran suspension (kept in an ice 
bath and constantly stirring) to ice-cold tubes (in an ice bath). 
NOTE: Add charcoal only to the number of tubes that the 
centrifuge carriers will accommodate for each run. DO NOT 
ADD CHARCOAL TO TCR OR RECOVERIES! 
 
B. Immediately vortex all tubes. 
C. Incubate tubes for 50 minutes at 4°C at 3600 rpm in the Beckman J-6 
M/E (JS-4.2 Rotor). 
 
D. Decant supernatant from each glass tube into corresponding plastic 
12x75mm tubes. Try not to spill around the edges of recipient tube. Wipe 
tubes with Kim Wipe before loading into gamma counter to avoid 
contamination. 
E. Count assay using a programmed estradiol protocol on gamma counter. 
 
